The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Asunaprevir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 Jul 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
- 21 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
- 24 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.